Imagine sitting down for a routine blood test and, instead of a compounder searching for a vein, a robot scans your arm, identifies the right vein, inserts the needle, fills the tubes and even puts on a bandage. That is no longer science fiction.
The US Food and Drug Administration (FDA) has authorised Aletta, the first standalone robotic device designed to draw blood from a patient’s arm without hands-on operator intervention.
The device, developed by Vitestro, is authorised for use in adults in outpatient settings. A trained phlebotomist must supervise the procedure, but one person can oversee up to three Aletta devices simultaneously — a development that could help address the shortage of trained phlebotomists in the US. A phlebotomist is a trained health worker who draws blood from patients for lab tests, blood donations, or medical research.
“This authorisation reflects the FDA’s commitment to advancing innovative medical devices that help meet a critical public health need while maintaining the safety and effectiveness patients deserve,” said Michelle Tarver, MD, PhD, director of the FDA’s Center for Devices and Radiological Health.
Blood collection is among the most common procedures performed in healthcare. Yet finding trained staff to carry it out has become increasingly difficult in some parts of the US, leading to delays for patients.
Aletta is designed to handle almost the entire blood-drawing process after a trained phlebotomist starts the session.
First, it guides the patient on how to position the arm. It then uses near-infrared light and Doppler ultrasound to scan the arm and identify a suitable vein while distinguishing it from an artery.
If the device cannot find an appropriate vein, it will not proceed with needle insertion.
Once a suitable vein is located, Aletta applies a tourniquet, prepares the skin, inserts the needle and collects the blood. It can also change collection tubes in the required sequence and place a bandage after the draw.
The supervising phlebotomist remains responsible for monitoring the procedure and checking that the tubes are filled correctly and in the right order.
Despite its robotic capabilities, Aletta is not designed to operate without human oversight.
The device has several safety measures built in. It continuously applies disinfectant to the skin during the ultrasound scan and is cleaned by trained staff between patients.
If a patient moves excessively during the procedure, the needle automatically detaches and the blood draw stops. Additional sensors can detect potentially unsafe conditions, pause the procedure and alert the supervising phlebotomist.
The FDA said clinical data showed that Aletta achieved successful blood-draw rates comparable to or better than trained human phlebotomists when it proceeded with a needle stick.
The trials included people with different health conditions, individuals who reported having difficult veins and participants with varying skin tones. Device-related adverse events were uncommon and generally mild.
The FDA’s decision comes as healthcare systems increasingly explore automation for routine procedures. Blood collection may appear simple, but difficult veins can turn a routine test into an uncomfortable experience, sometimes requiring multiple attempts.
By allowing one trained phlebotomist to supervise as many as three devices, Aletta could potentially allow healthcare facilities to serve more patients with the same workforce.
However, the technology is not being positioned as a replacement for phlebotomists. Human supervision remains mandatory, particularly to respond if the device encounters a problem or the patient needs assistance.
The authorisation also does not mean the robot can be used everywhere or on every patient. Its current approval covers adults in outpatient settings and comes with specific requirements for its use.
The FDA granted marketing authorisation to Vitestro through its De Novo pathway, which is used for novel medical devices considered low to moderate risk and for which there is no existing classification.
Along with the authorisation, the FDA has established special controls covering areas such as labelling, performance testing and clinical testing. These requirements, together with the agency’s general controls, are intended to provide reasonable assurance of safety and effectiveness.
For patients, the development could eventually mean fewer delays and a more consistent experience for a procedure that is a routine part of diagnosis and monitoring.
For healthcare systems facing staff shortages, it offers another possibility — using technology not to replace clinical workers, but to extend what a limited workforce can do.
The bigger significance of Aletta may therefore lie beyond a single blood test. As routine healthcare procedures become increasingly automated, the challenge will be to strike the right balance between machine precision, patient safety and human oversight.
For now, the needle may still be handled by a robot — but a trained human remains firmly in the loop.
